Viking Therapeutics Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
SG&A Expense
101.10
23,468.00
11,996.50
13,847.30
19,070.20
26,161
EBIT
101.10
23,468.00
11,996.50
13,847.30
19,070.20
26,161
Unusual Expense
20.60
2,212.50
10,425.30
1,064.20
344.90
1,398
Interest Expense
24.50
628.70
1,018.50
2,032.30
1,950.50
562
Pretax Income
146.20
21,884.20
23,404.00
14,731.80
20,577.70
22,063
Consolidated Net Income
146.20
21,884.20
23,404.00
14,731.80
20,577.70
22,063
Net Income
146.20
21,884.20
23,404.00
14,731.80
20,577.70
22,063
Net Income After Extraordinaries
146.20
21,884.20
23,404.00
14,731.80
20,577.70
22,063
Net Income Available to Common
146.20
21,884.20
23,404.00
14,731.80
20,577.70
22,063
EPS (Basic)
0.02
2.39
3.68
0.90
0.79
0.38
Basic Shares Outstanding
9,154.30
9,154.30
6,355.90
16,278.30
25,978.10
57,580.20
EPS (Diluted)
0.02
2.39
3.68
0.90
0.79
0.38
Diluted Shares Outstanding
9,154.30
9,154.30
6,355.90
16,278.30
25,978.10
57,580.20
EBITDA
101.10
23,468.00
-
13,847.30
19,070.20
26,161
Non-Operating Interest Income
-
-
36.30
83.60
98.10
3,274
About Viking Therapeutics
View Profile
